William Blair Increases Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Research analysts at William Blair raised their Q1 2025 EPS estimates for Cabaletta Bio in a report issued on Tuesday, April 1st. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.72). The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share. William Blair also issued estimates for Cabaletta Bio's Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.82) EPS, Q4 2026 earnings at ($0.74) EPS and FY2026 earnings at ($2.91) EPS.

Several other brokerages have also recently weighed in on CABA. HC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Tuesday, April 1st. Morgan Stanley dropped their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a report on Tuesday, April 1st. Evercore ISI cut Cabaletta Bio from an "outperform" rating to an "inline" rating and cut their target price for the stock from $15.00 to $6.00 in a research note on Friday, December 20th. UBS Group lowered their price target on Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $23.00 price objective on shares of Cabaletta Bio in a research report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Cabaletta Bio currently has a consensus rating of "Buy" and an average price target of $21.00.

Cabaletta Bio Stock Up 12.0 %

Shares of Cabaletta Bio stock traded up $0.13 on Friday, hitting $1.17. The stock had a trading volume of 373,925 shares, compared to its average volume of 1,492,371. Cabaletta Bio has a one year low of $0.99 and a one year high of $19.04. The stock's 50-day simple moving average is $1.90 and its two-hundred day simple moving average is $2.81. The stock has a market cap of $59.12 million, a price-to-earnings ratio of -0.54 and a beta of 2.44.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65).

Hedge Funds Weigh In On Cabaletta Bio

A number of institutional investors have recently added to or reduced their stakes in CABA. T. Rowe Price Investment Management Inc. grew its position in shares of Cabaletta Bio by 10.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,074,006 shares of the company's stock worth $9,248,000 after buying an additional 400,282 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in Cabaletta Bio by 19.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,634,473 shares of the company's stock worth $8,250,000 after purchasing an additional 597,828 shares during the period. Point72 Asset Management L.P. grew its holdings in Cabaletta Bio by 89.7% in the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company's stock worth $2,874,000 after purchasing an additional 598,607 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cabaletta Bio by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,110,702 shares of the company's stock valued at $2,522,000 after purchasing an additional 16,058 shares during the last quarter. Finally, Two Sigma Advisers LP increased its position in Cabaletta Bio by 195.8% during the 4th quarter. Two Sigma Advisers LP now owns 831,900 shares of the company's stock valued at $1,888,000 after buying an additional 550,700 shares in the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.